Personalized medicine and back–allogeneic exosomes for cancer immunotherapy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Extracellular vesicles, especially exosomes, have been explored for cancer immunotherapy. The initial studies made use of autologous B‐cell or dendritic cell‐derived exosomes, with the idea that MHC–peptide complexes on the exosomal surface would stimulate an MHC‐restricted cancer‐specific immune response. This was also verified in mouse systems, whilst the effects in human clinical systems were more modest. Several studies have explored the mechanisms for exosomal T‐cell activation, and a picture emerges where the antigen‐presenting cells, possibly both B cells and dendritic cells of the recipient, are needed to induce a potent T‐cell response to exosomes. Therefore, the exosomes function more as an adjuvant‐like delivery system of antigens, and we need to further understand the exact components that trigger the most broad and potent immune responses. Here, we describe the grounds for using allogeneic exosomes for cancer therapy, something that would greatly improve the feasibility of new exosome‐based immunotherapeutic approaches to cure cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of immune responses by extracellular vesicles
Robbins, P. D., & Morelli, A. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3622 · Cited by 2,260
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752
Dendritic cell-derived exosomes for cancer therapy.
Pitt, J. M., André, F., Amigorena, S., Soria, J.-C., Eggermont, A., Kroemer, G., & Zitvogel, L. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81137 · Cited by 636
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
André, F., Chaput, N., Schartz, N. E. C., Flament, C., Aubert, N., Bernard, J., Lemonnier, F., Raposo, G., Escudier, B., Hsu, D.-H., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2126 · Cited by 496
Cited by
Cancer treatment therapies: traditional to modern approaches to combat cancers
Kaur, R., Bhardwaj, A., & Gupta, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08809-3 · Cited by 561
Exosome-based immunotherapy: a promising approach for cancer treatment
Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 482
Engineered Extracellular Vesicles for Cancer Therapy
Zhang, X., Zhang, H., Gu, J., Zhang, J., Shi, H., Qian, H., Wang, D., Xu, W., Pan, J., & Santos, H. A. (2021) · Advanced Materials · doi:10.1002/adma.202005709 · Cited by 428
Xu, M., Ji, J., Jin, D., Wu, Y., Wu, T., Lin, R., Zhu, S., Jiang, F., Ji, Y., Bao, B., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.03.021 · Cited by 274
A review of current systems for annotation of cell and tissue images in digital pathology
Korzynska, A., Roszkowiak, L., Zak, J., & Siemion, K. (2021) · Biocybernetics and Biomedical Engineering · doi:10.1016/j.bbe.2021.04.012 · Cited by 26
Metadata
- Authors
- Samuel, M., & Gabrielsson, S.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2019-08-29
- Volume
- 289
- Issue
- 2
- Pages
- 138-146
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2966273234
- Cited by
- 70
- References
- 5
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Personalized medicine and back–allogeneic exosomes for cancer immunotherapy. https://app.cochat.ai/papers/10.1111/joim.12963
- The paper
- Samuel, M., & Gabrielsson, S. (2021). Personalized medicine and back–allogeneic exosomes for cancer immunotherapy. Journal of Internal Medicine. https://doi.org/10.1111/joim.12963
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.